HomeCompareSILK vs EPRT

SILK vs EPRT: Dividend Comparison 2026

SILK yields 7.28% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $31.0K in total portfolio value· pulled ahead in Year 4
10 years
SILK
SILK
● Live price
7.28%
Share price
$27.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$1,154.32
Full SILK calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SILK vs EPRT

📍 EPRT pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSILKEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SILK + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SILK pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SILK
Annual income on $10K today (after 15% tax)
$618.41/yr
After 10yr DRIP, annual income (after tax)
$981.17/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,933.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SILK + EPRT for your $10,000?

SILK: 50%EPRT: 50%
100% EPRT50/50100% SILK
Portfolio after 10yr
$47.9K
Annual income
$6,997.52/yr
Blended yield
14.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SILK
Analyst Ratings
3
Buy
7
Hold
3
Sell
Consensus: Hold
Price Target
$30.58
+11.2% upside vs current
Range: $20.00 — $46.00
Altman Z
4.6
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SILK buys
0
EPRT buys
0
No recent congressional trades found for SILK or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSILKEPRT
Forward yield7.28%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$32.4K$63.4K
Annual income after 10y$1,154.32$12,840.73
Total dividends collected$9.5K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$30.58$35.50

Year-by-year: SILK vs EPRT ($10,000, DRIP)

YearSILK PortfolioSILK Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,428$727.54$11,205$505.18+$223.00SILK
2$13,004$777.01$12,672$682.46+$332.00SILK
3$14,741$826.38$14,490$930.48+$251.00SILK
4← crossover$16,649$875.46$16,786$1,282.69$137.00EPRT
5$18,738$924.05$19,753$1,791.56$1.0KEPRT
6$21,022$971.98$23,677$2,541.64$2.7KEPRT
7$23,512$1,019.10$29,008$3,672.99$5.5KEPRT
8$26,223$1,065.28$36,463$5,425.08$10.2KEPRT
9$29,169$1,110.38$47,238$8,221.57$18.1KEPRT
10$32,366$1,154.32$63,385$12,840.73$31.0KEPRT

SILK vs EPRT: Complete Analysis 2026

SILKStock

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Full SILK Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SILK vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SILK vs SCHDSILK vs JEPISILK vs OSILK vs KOSILK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.